Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-controlled trial

Journal of Heart and Lung Transplantation

Volumn 29, Issue 2, 2010, Pages 137-149

  Hiremath, Jagdish ^a   Thanikachalam, Sadagopa ^b   Parikh, Keyur ^c   Shanmugasundaram, Somasundaram ^d   Bangera, Sudhakar ^e   Shapiro, Leland ^f   Pott, Gregory B ^f   Vnencak Jones, Cindy L ^g   Arneson, Carl ^h   Wade, Michael ^h   White, R James ⁱ  

^a Ruby Hall Clinic ^*  (India)

^b SRI RAMACHANDRA UNIVERSITY   (India)

^c SAL Hospital and Medical Institute   (India)

^d KS Hospital   (India)

^e Asian Clinical Trials Ltd   (India)

^f UNIVERSITY OF COLORADO   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h UNITED THERAPEUTICS CORPORATION   (United States)

ⁱ UNIVERSITY OF ROCHESTER   (United States)

Author keywords

angiopoietin; biomarkers; prostacyclin; pulmonary hypertension; six minute walk

Indexed keywords

ANGIOPOIETIN 2; ANTICOAGULANT AGENT; BASIC FIBROBLAST GROWTH FACTOR; DIGOXIN; DIURETIC AGENT; GELATINASE A; GELATINASE B; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AB; UNIPROST; VASCULOTROPIN; VASODILATOR AGENT;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DYSPNEA; EXERCISE TOLERANCE; FATIGUE; FEMALE; FEVER; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; INSOMNIA; JAW PAIN; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; VOMITING; WALKING;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; EPOPROSTENOL; EXERCISE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PHYSICAL ENDURANCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WALKING;

EID: 74849116556     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.09.005     Document Type: Article

References (46)

1. Farber H.W., and Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 351 (2004) 1655-1665
2. McLaughlin V.V., and McGoon M.D. Pulmonary arterial hypertension. Circulation 114 (2006) 1417-1431
3. Tuder R.M., Marecki J.C., Richter A., et al. Pathology of pulmonary hypertension. Clin Chest Med 28 (2007) 23-42
4. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334 (1996) 296-302
5. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
6. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
7. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
8. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
9. Newman J.H., Fanburg B.L., Archer S.L., et al. Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation 109 (2004) 2947-2952
10. Humbert M., Morrell N.W., Archer S.L., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43 suppl (2004) 13S-24S
11. Kawut S.M., Horn E.M., Berekashvili K.K., et al. von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. Chest 128 (2005) 2355-2362
12. Austin E.D., and Loyd J.E. Genetics and mediators in pulmonary arterial hypertension. Clin Chest Med 28 (2007) 43-57
13. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132 (2000) 425-434
14. Califf R.M., Adams K.F., McKenna W.J., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 134 (1997) 44-54
15. Laliberte K., Arneson C., Jeffs R., et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 44 (2004) 209-214
16. McSwain C.S., Benza R., Shapiro S., et al. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. J Clin Pharmacol 48 (2008) 19-25
17. Tapson V.F., Gomberg-Maitland M., McLaughlin V.V., et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 129 (2006) 683-688
18. Gomberg-Maitland M., Tapson V.F., Benza R.L., et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 172 (2005) 1586-1589
19. Badesch D.B., Abman S.H., Ahearn G.S., et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 suppl (2004) 35S-62S
20. Badesch D.B., Abman S.H., Simonneau G., et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131 (2007) 1917-1928
21. Barst R.J., Gibbs J.S., Ghofrani H.A., et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54 suppl (2009) S78-S84
22. Deaver D.R. A new non-isotopic detection system for immunoassays. Nature 377 (1995) 758-760
23. Puren A.J., Fantuzzi G., Gu Y., et al. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest 101 (1998) 711-721
24. Cogan J.D., Vnencak-Jones C.L., Phillips III J.A., et al. Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension. Genet Med 7 (2005) 169-174
25. Feinstein A.R., Fisher M.B., and Pigeon J.G. Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. Am J Cardiol 64 (1989) 50-55
26. Mahler D.A., Weinberg D.H., Wells C.K., et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 85 (1984) 751-758
27. Newman J.H., Wheeler L., Lane K.B., et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 345 (2001) 319-324
28. Lewis J.A., Jonsson B., Kreutz G., et al. Placebo-controlled trials and the Declaration of Helsinki. Lancet 359 (2002) 1337-1340
29. Hollon T. FDA uneasy about placebo revision. Nat Med 7 (2001) 7
30. Thomson J.R., Machado R.D., Pauciulo M.W., et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 37 (2000) 741-745
31. Sztrymf B., Coulet F., Girerd B., et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 177 (2008) 1377-1383
32. Humbert M., Monti G., Brenot F., et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151 (1995) 1628-1631
33. Eddahibi S., Humbert M., Sediame S., et al. Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. Am J Respir Crit Care Med 162 (2000) 1493-1499
34. Benisty J.I., McLaughlin V.V., Landzberg M.J., et al. Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. Chest 126 (2004) 1255-1261
35. Damas J.K., Otterdal K., Yndestad A., et al. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation 110 (2004) 999-1005
36. Lim H.S., Lip G.Y., and Blann A.D. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 180 (2005) 113-118
37. Du L., Sullivan C.C., Chu D., et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 348 (2003) 500-509
38. Dewachter L., Adnot S., Fadel E., et al. Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension. Am J Respir Crit Care Med 174 (2006) 1025-1033
39. Hildbrand P., Cirulli V., Prinsen R.C., et al. The role of angiopoietins in the development of endothelial cells from cord blood CD34+ progenitors. Blood 104 (2004) 2010-2019
40. Lobov I.B., Brooks P.C., and Lang R.A. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 99 (2002) 11205-11210
41. Lim H.S., Blann A.D., Chong A.Y., et al. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 27 (2004) 2918-2924
42. Tuder R.M., Groves B., Badesch D.B., et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144 (1994) 275-285
43. Cool C.D., Stewart J.S., Werahera P., et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 155 (1999) 411-419
44. McLaughlin V.V., Genthner D.E., Panella M.M., et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338 (1998) 273-277
45. Humbert M., Monti G., Fartoukh M., et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 11 (1998) 554-559
46. Schermuly R.T., Dony E., Ghofrani H.A., et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115 (2005) 2811-2821